HOMAGE

APPREMED actively participated in the HOMAGE project, in particular in the construction of the database, statistical analysis and authoring or co-authoring publications. 

HOMAGE is a multicentre open-label trial with blinded endpoint evaluation (registration number: NCT02556450), conducted in nine centers in the United Kingdom, France, Italy, Ireland, Germany and the Netherlands.  Each centre had its own recruitment strategies.  The protocol was approved by the Greater Manchester Central Research Ethics Committee (reference, 16/NW/0012; EudraCT number: 2015-000413-48) as well as by each center’s local Ethics Committee.  Patients of either sex, aged ≥60 years were eligible, provided that they were at increased risk of developing heart failure, because they already had or were likely to develop coronary heart disease.  Additionally, eligible patients had to have a serum N‑terminal pro B‑type natriuretic peptide (NT‑proBNP) of 125-1000 ng/L or a serum BNP of 35-280 ng/L.  These ranges excluded patients at low heart failure risk as well as those with advanced disease requiring further investigation and treatment.    For more information, refer to Cleland JGF et al.  Eur Heart J. 2021;42:684-696.

 

Yu YL, Siwy J, An DW, González A, Hansen T, Latosinska A, Pellicori P, Ravassa S, Mariottoni B, Verdonschot JAJ, Ahmed F, Petutschnigg J, Rossignal P, Heymans S, Cuthbert JJ, Girerd N, Clark AL, Verhamme P, Nawrot TS, Janssens S, Cleland JG, Zannad F, Díez J, Mischak H, Ferreira JP, Staessen JA, on behalf of the HOMAGE investigators.  Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial.  Heart 2024; 110: 1180-1187 (doi: 10. 1136/ heartjnl- 2023-323796)

24-06-P  (link to full text)

Wei FF, Mariottoni B, An DW, Pellicori P, Yu YL, Verdonschot JAJ, Liu C, Ahmed FZ, Petutschnigg J, Rossignol P, Heymans S, Cuthbert J, Girerd N, Li Y, Clark AL, Nawrot TS, Ferreira JP, Zannad F, Cleland JGF, Staessen JA, on behalf of the HOMAGE investigators.   Effects of spironolactone on exercise blood pressure in patients atincreased risk of developing heart failure: report from the HOMAGE trial. 
Hypertension Research 2024; 47: doi: 10.1038/s41440-024-01843-z (Epub ahead of print). 

24-21-P   (link to full text)

Wei FF, Mariottoni B, An DW, Pellicori P, Yu YL, Verdonschot JAJ, Liu C, Ahmed FZ, Petutschnigg J, Rossignol P, Heymans S, Cuthbert J, Girerd N, Li Y, Clark AL, Nawrot TS, Ferreira JP, Zannad F, Cleland JGF, Staessen JA, on behalf of the HOMAGE investigators.  Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure.  ESC Heart Failure 2024; 11: doi: 10.1002/ehf2.15000 (Epub ahead of publication).

24-18-P   (link to full text)